Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2025, titled "Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg".
Press Release Aug 11 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Aug 08 2025
- Press Release Aug 07 2025
- Press Release Jul 29 2025
- Press Release Jul 24 2025
- Press Release 17-07-2025 NewspaperpublicationAGMnotice17072025
Later from Zydus Lifesciences
- Press Release Aug 12 2025
- Press Release Aug 13 2025
- Press Release 20-08-2025 Newspaperadvertisement20082025
- Zydus Therapeutics Reports Positive Topline Results from EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis
- Press Release Aug 29 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences